Want to see VYGR full AI Analyst Report?
Top Page
Voyager Therapeutics
(NASDAQ:VYGR)
Select Model
Select Model
Rating:44Neutral
Price Target:
$3.50
▲(12.90% Upside)
Action:Reiterated
Date:07/13/26
The score is primarily held down by weak financial performance—sharp profitability deterioration and large ongoing cash burn—despite manageable leverage. Technicals also lean bearish with the stock trading below major moving averages and negative MACD. Positive corporate catalysts (IND clearance and encouraging preclinical data) provide some support but do not fully offset the near-term funding and loss profile; valuation is also constrained by negative earnings and no dividend.
Positive Factors
Platform & BBB delivery
Identification of ALPL as a mediator of IV-to-CNS transport is a durable platform strength. It supports systemic, one-time dosing with broad CNS distribution, lowering translational risk versus unknown delivery mechanisms and giving a repeatable technical edge for neurological gene therapies.
Negative Factors
High cash burn
Sustained negative operating and free cash flow at this scale creates persistent funding need. Over months this forces reliance on external capital, increases dilution risk, constrains the ability to advance multiple programs, and heightens execution risk if markets or partners delay financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform & BBB delivery
Identification of ALPL as a mediator of IV-to-CNS transport is a durable platform strength. It supports systemic, one-time dosing with broad CNS distribution, lowering translational risk versus unknown delivery mechanisms and giving a repeatable technical edge for neurological gene therapies.
Read all positive factors
Voyager Therapeutics (VYGR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$183.08M
Dividend YieldN/A
Average Volume (3M)714.30K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue Growth-45.50%
EPS Growth-35.63%
CountryUS
Employees141
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.98
Shares Outstanding60,421,288
10 Day Avg. Volume752,857
30 Day Avg. Volume714,297
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.18
Price to Sales (P/S)5.71
P/FCF Ratio-1.71
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.00Price Target Upside448.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.74
Revenue Forecast (FY)$39.27M
Voyager Therapeutics Business Overview & Revenue Model
Company Description
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label ...
How the Company Makes Money
Voyager Therapeutics does not primarily generate revenue from commercial product sales because its pipeline is in clinical/early development; instead, it historically makes money mainly through collaboration and licensing arrangements with larger ...
Voyager Therapeutics Earnings Call Summary
Earnings Call Date:Mar 11, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with significant advancements and strong financial positioning. Despite a setback in the SOD1 silencing program, the progress in tau-targeting therapies and potential substantial milestone payments from partnerships highlight a promising future.Positive Updates
Strong Cash Position and Potential Milestone Payments
Voyager Therapeutics reported $332 million in cash as of the end of 2024, with potential future milestone payments totaling $8.2 billion from partnerships.
Negative Updates
Setback in SOD1 Silencing Gene Therapy Program
The SOD1 silencing gene therapy program moved back into the research stage due to the payload not meeting the target profile, requiring the identification of a new payload.
Read all updates
Q4-2024 Updates
Positive
Negative
Strong Cash Position and Potential Milestone Payments
Voyager Therapeutics reported $332 million in cash as of the end of 2024, with potential future milestone payments totaling $8.2 billion from partnerships.
Read all positive updates
Company Guidance
During the Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call, the company provided several key metrics and updates about their progress and future plans. Voyager reported $332 million in cash as of the end of 2024 and highlighted potential future milestone payments totaling $8.2 billion, emphasizing the significance of their partnerships as a source of non-dilutive revenue. The company is advancing its tau silencing gene therapy, VY1706, into IND-enabling studies, targeting IND submission in 2026, with promising non-human primate study results showing 50% to 73% knockdown of tau messenger RNA across the brain. Additionally, the anti-tau antibody, VY7523, showed favorable results in a single ascending dose study, with a CSF to serum ratio of 0.3%. Voyager expects initial tau PET data from a multiple ascending dose study in Alzheimer's patients in the second half of 2026. They also noted their $2.9 billion in developmental milestones and guidance extending their cash runway to mid-2027.Voyager Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.49M | 40.37M | 80.00M | 250.01M | 40.91M | 37.41M |
| Gross Profit | -65.19M | -91.90M | 80.00M | 157.84M | -14.86M | -36.37M |
| EBITDA | -112.54M | -115.52M | -59.61M | 138.18M | -39.65M | -66.03M |
| Net Income | -116.64M | -119.72M | -65.00M | 132.33M | -46.41M | -71.20M |
Balance Sheet | ||||||
| Total Assets | 219.32M | 252.28M | 393.05M | 351.28M | 159.36M | 193.85M |
| Cash, Cash Equivalents and Short-Term Investments | 141.48M | 196.45M | 266.68M | 230.88M | 118.85M | 132.54M |
| Total Debt | 34.57M | 36.50M | 43.73M | 20.29M | 23.13M | 44.18M |
| Total Liabilities | 45.66M | 56.20M | 93.29M | 114.96M | 100.34M | 98.80M |
| Stockholders Equity | 173.67M | 196.08M | 299.76M | 236.32M | 59.02M | 95.06M |
Cash Flow | ||||||
| Free Cash Flow | -129.94M | -135.06M | -18.83M | 74.66M | -15.00M | -55.13M |
| Operating Cash Flow | -127.99M | -132.47M | -15.31M | 77.92M | -12.51M | -53.52M |
| Investing Cash Flow | 92.35M | 125.45M | -94.86M | -141.64M | -7.34M | 65.91M |
| Financing Cash Flow | 4.07M | 816.00K | 114.02M | 33.65M | 1.11M | 612.00K |
Voyager Therapeutics Technical Analysis
Negative
3.10
Price Trends
3.47
Negative
3.74
Negative
3.93
Negative
Market Momentum
-0.15
Positive
38.37
Neutral
27.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYGR, the sentiment is Negative. The current price of 3.1 is below the 20-day moving average (MA) of 3.24, below the 50-day MA of 3.47, and below the 200-day MA of 3.93, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 38.37 is Neutral, neither overbought nor oversold. The STOCH value of 27.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VYGR.
Voyager Therapeutics Risk Analysis
Voyager Therapeutics disclosed 74 risk factors in its most recent earnings report. Voyager Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Voyager Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $495.49M | -2.43 | -121.71% | ― | ― | ― | |
55 Neutral | $229.18M | -1.35 | 194.13% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $443.81M | -2.23 | -81.87% | ― | ― | 2.58% | |
44 Neutral | $183.08M | -1.53 | -55.97% | ― | -45.50% | -35.63% | |
44 Neutral | $195.59M | -7.30 | 21.05% | ― | ― | 43.38% | |
44 Neutral | $160.64M | -1.58 | -80.56% | ― | ― | 59.42% |
* Healthcare Sector Average
VYGR
Voyager Therapeutics
3.03
-0.18
-5.61%
GALT
Galectin Therapeutics
2.97
-0.62
-17.27%
RNAC
Cartesian Therapeutics
7.80
-4.68
-37.50%
SLN
Silence Therapeutics
10.49
4.54
76.30%
TNYA
Tenaya Therapeutics
0.74
0.05
6.78%
KYTX
Kyverna Therapeutics, Inc.
7.30
3.93
116.62%
Voyager Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Voyager Therapeutics advances tau-silencing gene therapy program
Positive
Jul 13, 2026
On July 13, 2026, Voyager Therapeutics presented three- and six-month good laboratory practice toxicology data for its investigational tau-silencing gene therapy VY1706 at the Alzheimer’s Association International Conference, showing a favor...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Voyager Therapeutics Expands Authorized Shares After Stockholder Vote
Positive
Jun 10, 2026
On June 9, 2026, Voyager Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the company’s certificate of incorporation to nearly double its authorized capital stock and common shares,...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Voyager Therapeutics IND Cleared for Alzheimer’s Gene Therapy
Positive
Jun 1, 2026
On June 1, 2026, Voyager Therapeutics, Inc. reported that the U.S. Food and Drug Administration cleared its Investigational New Drug application for VY1706, an investigational tau-silencing gene therapy designed to target intracellular and extrace...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.